Developer docs
API playgroundTry for free, no card

Search company profiles

Advaxis

Full company profile

uuid000463z

Namestring
Advaxis
Legal namestring
Advaxis, Inc.
Websiteurl
advaxis.com
Company typeenum
Private
Founded yearint
2002
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cancer immunotherapy, HPV-associated cancer therapy, proprietary immunotherapy platform, biopharmaceutical development, personalized cancer vaccines
Industry3 codes
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy / Oncology Biopharmaceuticals
Social media profiles3 records
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Advaxis is a biotechnology company developing multiple cancer immunotherapies built on its proprietary platform that redirects the immune system to attack cancer cells. The company's pipeline focuses primarily on immunotherapies for HPV-associated cancers, including cervical cancer, and extends to personalized cancer vaccines. It operates as a clinical-stage biopharmaceutical developer with drug candidates in oncology.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Advaxis, Inc. is a Delaware-incorporated biotechnology company. Based on the available sources, no specific products, services, or modules are named. The company operates in the biotechnology and cancer immunotherapy space, as evidenced by its presence in HPV-associated cancer and personalized cancer vaccine market research reports.

Product and service2 records
1Proprietary Listeria-based Cancer Immunotherapy Platform
CategoryCancer immunotherapy / oncology biopharmaceuticals
Description

A proprietary immunotherapy platform that redirects the immune system to kill cancer cells, used to develop multiple oncology drug candidates including therapies for HPV-associated cancers such as cervical cancer. Targeted at clinical development and pharmaceutical licensing partners.

2HPV-Associated Cervical Cancer Immunotherapy Candidates
CategoryCancer immunotherapy / oncology biopharmaceuticals
Description

Immunotherapy drug candidates built on the company's proprietary platform for the treatment of HPV-associated cervical cancer in patients with limited therapeutic alternatives. Targeted at clinical development toward eventual commercialization and licensing to pharmaceutical partners.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Develops immunotherapies and vaccines including cancer immunotherapy programs (e.g., CV301), making it a direct competitor in the therapeutic cancer vaccine space.

TypeDirect peer
Description

Cancer vaccine developer focused on neoantigen immunotherapies, directly comparable to Advaxis as a small-cap, clinical-stage biotech pursuing immuno-oncology vaccines.

TypeDirect peer
Description

TCR-based immunotherapy company with approved tebentafusp in melanoma; comparable in modality (redirected immune killing) and oncology focus, though with a different molecular scaffold.

TypeDirect peer
Description

Developer of DNA-based immunotherapies for cancer and infectious diseases, including HPV-related cervical dysplasia (VGX-3100). Directly comparable as a clinical-stage immuno-oncology vaccine developer.

TypeDirect peer
Description

Focused on tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumors including cervical cancer; comparable as a small-cap clinical-stage oncology biotech pursuing novel immuno-oncology mechanisms.

TypeEmerging player
Description

Develops arenavirus-based immunotherapies for cancer and infectious disease; comparable as a clinical-stage platform company using viral vectors to redirect immune responses, similar mechanistic paradigm to Advaxis's Listeria approach.

TypeBroad incumbent
Description

Keytruda (pembrolizumab) is approved in cervical cancer and dominates the immuno-oncology landscape. Advaxis competes for the same patient population and combination opportunities.

8Bristol-Myers Squibb
TypeBroad incumbent
Description

Owns Opdivo and Yervoy checkpoint inhibitors approved across multiple tumors including cervical cancer; broad incumbent whose IO franchise defines the standard against which Advaxis must position.

TypeBroad incumbent
Description

mRNA platform company with an expanding oncology vaccine pipeline (e.g., mRNA-4157). Comparable as a platform immunotherapy developer, though with substantially larger resources and broader indications.

10BioNTech
TypeBroad incumbent
Description

mRNA immunotherapy company with FixVac and individualized neoantigen programs in oncology; comparable as a platform-based cancer immunotherapy developer with substantially greater scale and resources.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Advaxis

Cancer Immunotherapy / Oncology Biopharmaceuticalsadvaxis.com

Advaxis firmographics

Firmographics
Name
Advaxis
Legal name
Advaxis, Inc.
Website
https://advaxis.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Advaxis industry classification

Industry
Product category
Cancer Immunotherapy / Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Cancer immunotherapy
  • HPV-associated cancer therapy
  • Proprietary immunotherapy platform
  • Biopharmaceutical development
  • Personalized cancer vaccines

Where Advaxis is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Markets served

Advaxis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Advaxis product offering

Product offering

Core offering

Advaxis is a biotechnology company developing multiple cancer immunotherapies built on its proprietary platform that redirects the immune system to attack cancer cells. The company's pipeline focuses primarily on immunotherapies for HPV-associated cancers, including cervical cancer, and extends to personalized cancer vaccines. It operates as a clinical-stage biopharmaceutical developer with drug candidates in oncology.

Product overview

Advaxis, Inc. is a Delaware-incorporated biotechnology company. Based on the available sources, no specific products, services, or modules are named. The company operates in the biotechnology and cancer immunotherapy space, as evidenced by its presence in HPV-associated cancer and personalized cancer vaccine market research reports.

Differentiator

Problem solved

Functional benefit

Products and services

  • Proprietary Listeria-based Cancer Immunotherapy Platform A proprietary immunotherapy platform that redirects the immune system to kill cancer cells, used to develop multiple oncology drug candidates including therapies for HPV-associated cancers such as cervical cancer. Targeted at clinical development and pharmaceutical licensing partners.
  • HPV-Associated Cervical Cancer Immunotherapy Candidates Immunotherapy drug candidates built on the company's proprietary platform for the treatment of HPV-associated cervical cancer in patients with limited therapeutic alternatives. Targeted at clinical development toward eventual commercialization and licensing to pharmaceutical partners.

Companies that use Advaxis

Customer profile

Segments1 record

Ideal customer profiles1 record

Advaxis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Advaxis partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights3 records

Advaxis competitors and assessment

Company assessment

Direct peers

  • Bavarian Nordic: Develops immunotherapies and vaccines including cancer immunotherapy programs (e.g., CV301), making it a direct competitor in the therapeutic cancer vaccine space.
  • Genocea Biosciences: Cancer vaccine developer focused on neoantigen immunotherapies, directly comparable to Advaxis as a small-cap, clinical-stage biotech pursuing immuno-oncology vaccines.
  • Immunocore: TCR-based immunotherapy company with approved tebentafusp in melanoma; comparable in modality (redirected immune killing) and oncology focus, though with a different molecular scaffold.
  • Inovio Pharmaceuticals: Developer of DNA-based immunotherapies for cancer and infectious diseases, including HPV-related cervical dysplasia (VGX-3100). Directly comparable as a clinical-stage immuno-oncology vaccine developer.
  • Iovance Biotherapeutics: Focused on tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumors including cervical cancer; comparable as a small-cap clinical-stage oncology biotech pursuing novel immuno-oncology mechanisms.

Emerging players

  • Genocea (Helixor) / Hookipa Pharma: Develops arenavirus-based immunotherapies for cancer and infectious disease; comparable as a clinical-stage platform company using viral vectors to redirect immune responses, similar mechanistic paradigm to Advaxis's Listeria approach.

Broad incumbents

  • Merck & Co. Keytruda (pembrolizumab) is approved in cervical cancer and dominates the immuno-oncology landscape. Advaxis competes for the same patient population and combination opportunities.
  • Bristol-Myers Squibb: Owns Opdivo and Yervoy checkpoint inhibitors approved across multiple tumors including cervical cancer; broad incumbent whose IO franchise defines the standard against which Advaxis must position.
  • Moderna: mRNA platform company with an expanding oncology vaccine pipeline (e.g., mRNA-4157). Comparable as a platform immunotherapy developer, though with substantially larger resources and broader indications.
  • BioNTech: mRNA immunotherapy company with FixVac and individualized neoantigen programs in oncology; comparable as a platform-based cancer immunotherapy developer with substantially greater scale and resources.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Advaxis social profiles

Digital presence

Advaxis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Advaxis leadership team

Management profile

Number of profiles

Profiles10 records

Advaxis funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Advaxis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advaxis

What does Advaxis do?

Advaxis is a biotechnology company developing multiple cancer immunotherapies built on its proprietary platform that redirects the immune system to attack cancer cells. The company's pipeline focuses primarily on immunotherapies for HPV-associated cancers, including cervical cancer, and extends to personalized cancer vaccines. It operates as a clinical-stage biopharmaceutical developer with drug candidates in oncology.

When was Advaxis founded?

Advaxis was founded in 2002. It employs 51 to 100 people.

Where is Advaxis based?

Advaxis is headquartered in Princeton, United States, in the North America region.

Who are Advaxis's main competitors?

Direct peers on record are Bavarian Nordic, Genocea Biosciences, Immunocore, Inovio Pharmaceuticals and Iovance Biotherapeutics. Genocea (Helixor) / Hookipa Pharma is listed as an emerging player. Broad incumbents are Merck & Co., Bristol-Myers Squibb, Moderna and BioNTech.

Does Advaxis have an API?

No public API is recorded for Advaxis.

What industry is Advaxis in?

Advaxis's product category is Cancer Immunotherapy / Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy), with a secondary code of HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0OS Therapies: Acquisition Of Advaxis Immunotherapies Assets CompletedOS Therapies completed acquisition of Advaxis Immunotherapies' listeria-based cancer immunotherapy assets from Ayala Pharmaceuticals. The company now leads the platform, with OST-HER2 targeting year-end 2025 approval for osteosarcoma recurrence prevention. The platform's manufacturing-based IP is protected through 2040.NJBIZAdvaxis completes merger to become Ayala PharmaceuticalsAdvaxis Inc. has completed its merger with Ayala Pharmaceuticals Inc., creating a new entity that will operate under the name Ayala Pharmaceuticals. The combined company will focus on the development and commercialization of Ayala's lead program, AL102, aimed at treating desmoid tumors, and plans to pursue a Nasdaq uplisting, though success is not guaranteed.GlobeNewswireAdvaxis and Ayala Pharmaceuticals Complete MergerAdvaxis and Ayala Pharmaceuticals completed their merger, with the combined entity operating under the name Ayala Pharmaceuticals and focusing on the development of its lead program AL102 for desmoid tumors. The merged company will continue trading on the OTC markets under the symbol ADXS while seeking to uplist to Nasdaq. Leadership roles were assigned to existing executives from Advaxis, including Kenneth A. Berlin as CEO.FierceBiotechAdvaxis spies merger with Ayala as route back to NasdaqAdvaxis agreed to merge with Ayala, combining their cash and clinical programs to pursue a Nasdaq listing. The combined company will prioritize AL102 for desmoid tumors and ADXS-504 for prostate cancer, with $20 million in cash. Advaxis CEO Kenneth Berlin said the funds should cover key milestones in 2023.BenzingaAyala Pharmaceuticals and Advaxis Agree To Combine, Expect Uplisting On NASDAQAyala Pharmaceuticals Inc and Advaxis Inc have announced a merger agreement that will combine both companies under Ayala stockholders owning approximately 62.5% of the merged entity. The combined company will focus on developing Ayala's AL102 for desmoid tumors and Advaxis's ADXS-504 for prostate cancer, with plans to seek an uplisting to Nasdaq. Key leadership changes are expected, with Kenneth Berlin from Advaxis becoming President and CEO of the combined company.BioSpaceAyala Pharmaceuticals and Advaxis Enter into Merger AgreementAyala Pharmaceuticals and Advaxis entered a definitive merger agreement, with Ayala shareholders owning about 62.5% and Advaxis shareholders 37.5% of the combined company. The deal aims to advance Ayala's AL102 for desmoid tumors and Advaxis's ADXS-504 for prostate cancer, with a conference call scheduled today.ZapierImmunotherapy nano-cap Advaxis withdraws $9 million Nasdaq uplistingAdvaxis withdrew its Nasdaq IPO plans on Monday, having filed in May 2022. The company had planned to raise $9 million by offering 2.5 million shares at $3.70. Its pipeline includes ADXS-503 for lung cancer and ADXS-504 for prostate cancer.BioSpaceAdvaxis, Inc. Announces 1-for-80 Reverse Stock SplitAdvaxis, Inc. filed a certificate to implement a one-for-80 reverse stock split, effective June 6, 2022, with trading on a split-adjusted basis. The split aims to support an upcoming Nasdaq Capital Market listing and provide more authorized shares for financing. The listing remains subject to Nasdaq approval.GlobeNewswireAdvaxis, Inc. Announces 1-for-80 Reverse Stock SplitAdvaxis filed a certificate of amendment to implement a one-for-80 reverse stock split, effective June 6, 2022. The split aims to support an upcoming Nasdaq Capital Market listing and enable additional financing. The company expects the split to help prepare for clinical milestones for its lead assets.ZapierImmunotherapy biotech Advaxis sets terms for $8 million Nasdaq uplistingAdvaxis announced terms for its Nasdaq uplisting, raising $8 million by offering 1.5 million units at $5.44 each. The company plans to list under ADXS, with a market value of $18 million. Its pipeline includes ADXS-503 for lung cancer and ADXS-504 for prostate cancer.